Abstract
Anabolic skeletal agents have recently broadened our therapeutic options for osteoporosis. By directly stimulating bone formation, they reduce fracture incidence by improving bone qualities in addition to increasing bone mass. Teriparatide [recombinant human parathyroid hormone(1–34)], the only anabolic agent currently approved in the United States for osteoporosis, has emerged as a major therapeutic approach to selected patients with osteoporosis. Teriparatide is approved for both postmenopausal women and men with osteoporosis who are at high risk for fracture. With the use of this anabolic agent, bone density and bone turnover increase, microarchitecture improves, and bone size is beneficially altered. The incidence of vertebral and nonvertebral fractures is reduced with teriparatide use. Combination therapy with parathyroid hormone and an antiresorptive does not appear to offer definitive advantages over the use of PTH or an antiresorptive alone, although recent ideas about combining these agents may offer new insights. In order to maintain increases in bone density acquired during PTH therapy, it is important to follow its use with an antiresorptive agent.
Similar content being viewed by others
Abbreviations
- BMD:
-
bone mineral density
- BMI:
-
body mass index
- DXA:
-
dual X-ray absorptiometry
- FDA:
-
Food and Drug Administration
- GH:
-
growth hormone
- GIO:
-
glucocorticoid-induced osteoporosis
- IGF-1:
-
insulin-like growth factor
- IGFBP-3:
-
insulin-like growth factor binding protein-3
- PTH:
-
parathyroid hormone
- QCT:
-
quantitative computed tomography
- rhIGF-1:
-
recombinant human insulin-like growth factor
References
Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005;353 6:595–603
Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003;14 1:2–12
Lindsay R, Cosman F. The pharmacology of estrogens in osteoporosis. In: Bilezikian JP Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic; 1996. pp. 1063–8
Fleisch H. Bisphosphonates: mechanisms of action and clinical use. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic; 1996. pp. 1037–52
Hodsman AB, Bauer DC, Dempster D, Dian L, Hanley DA, Harris ST, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005
Albright F, Aub JC, Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventenn proven cases from one clinic. JAMA 1934;102:1276–87
Albright F, Reifenstein EC. The parathyroid glands and metabolic bone disease. Baltimore: Williams & Wilkins; 1948
Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999;84 5:1562–6
Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006;21 3:366–73
Rubin M, Bilezikian J. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 2002;19:415–32
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16 10:1846–53
Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, Frame B, Rao DS. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983;72 4:1396–409
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18 11:1932–41
Recker R, Bare S, Miller M, Newman M, Fox J. Treatment of osteoporotic women with parathyroid hormone 1–84 for 18 months improves cancellous bone formation and structure; a bone biopsy study. Bone Min Res 2004;19 supp 1:S97
Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone(1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16 1:157–65
Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002;17 10:1741–3
Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990;8 4:612–7
Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18 3:539–43
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. Jama 2001;285 3:320–3
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344 19:1434–41
Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87 10:4528–35
Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005;90 3:1583–7
Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18 1:18–23
Delmas P, Licata A, Crans G, Chen P, Misurski D, Wagman R, et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. J Bone Miner Res 2004;19 supp 1:1170
Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20 9:1507–13
Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, et al. Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88 11:5212–20
Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau I. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 2005;5 4:356–7
Ettinger M, Greenspan S, Marriott TB, Hanley DA, Zanchetta JR, Bone, HG 3rd, et al. PTH(1–84) prevents first vertebral fracture in postmenopausal women with osteoporosis: results from the TOP study. American College of Rheumatology Annual Meeting 2004;L17
Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85 9:3069–76
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18 1:9–17
Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2004
Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16 5:925–31
Roe E, Sanchez S, del Puerto G, Pierini E, Bacchetti P, Cann C, et al. Parathyroid hormone 1–34 (hPTH 1–34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis—results from a placebo-controlled randomized trial. J Bone Miner Res 1999;14 suppl 1:S137
Ettinger, B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19 5:745–51
Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13 6:1051–5
Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R. Effects of PTH rechallenge 1 year after the first PTH course in patients on long-term alendronate. 27th Annual Meeting of the American Society for Bone and Mineral Research, Nashville, Tennessee, 2005(Presentation Number: 1079)
Rubin MR, Bilezikian JP. Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002;87 9:4033–41
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102 8:1627–33
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349 13:1207–15
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349 13:1216–26
Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20 11:1905–11
Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003;88 3:1150–6
Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164 18:2024–30
Lindsay R, Scheele WH, Clancy AD, Hossain A, Mitlak BH. Reduction in nonvertebral fragility fractures and increase in spinal bone density is maintained 31 months after discontinuation of recombinant human parathyroid hormone (1–34) in postmenopausal women with osteoporosis. 84th Annual Meeting of the Endocrine Society. San Francisco, California; 2002. pp. OR35–6
Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350 9077:550–5
Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporos Int 2004
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000;15 5:944–51
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005;353 6:555–65
Neer R, Arnaud CD, Zanchetta J, Prince R, Gaich G, Reginster JY, et al. Recombinant human PTH [rhPTH(1–34)] reduces the risk of spine and non-spine fractures in postmenopausal osteoporosis (abstract). 82nd Annual Meeting of the Endocrine Society, 2000
Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone Neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32 4:426–38
Wilker C, Jolette J, Smith S, Doyle N, Hardisty J, Metcalfe AJ, et al. A no observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH(1–84) for 2 years: role of the C-terminal PTH receptor? J Bone Miner Res 2004;19 supp 1:SA435
Betancourt M, Wirfel KL, Raymond AK, Yasko AW, Lee J, Vassilopoulou-Sellin R. Osteosarcoma of bone in apatient with primary hyperparathyroidism: a case report. J Bone Miner Res 2003;18 1:163–6
Jimenez C, Kim W, Al Sagier F, El Naggar A, Sellin R, Berry D, et al. Primary hyperparathyroidism and osteosarcoma: examination of a large osteosarcoma cohort identifies unique characteristics. J Bone Miner Res 2003;18 suppl 2:LB6
Palmer M, Adami HO, Krusemo UB, Ljunghall S. Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am J Epidemiol 1988;127 5:1031–40
Smith J, Huvos AG, Chapman M, Rabbs C, Spiro RH. Hyperparathyroidism associated with sarcoma of bone. Skelet Radiol 1997;26 2:107–12
Tashjian AH Jr, Gagel RF. Teriparatide [Human PTH(1–34)]: 2.5 years of experience on the use and safely of the drug for the treatment of osteoporosis. J Bone Miner Res 2006;21 3:354–65
Wiig JN, Bakken TS. Hyperparathyroidism with multiple malignant tumours of bone with giant-cells. A case report. Acta Chir Scand 1971;137 4:391–3
Gopalakrishnan V, Hwang S, Loughre H, Alexandre B, Deai D, Haiying L, et al. Administration of ThPTH to humans using Macroflux transdermal technology reults in the rapid delivery of biologically active PTH. J Bone Miner Res 2004;19 supp 1:M484
Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, et al. Oral delivery of biologically active parathyroid hormone. Pharm Res 2001;18 7:964–70
Mehta NM, Gilligan, JP, Stern, B, Ray, MVL, Meenan, CP, Consalvo, AP, et al. Biological activity of recombinant PTH analog 7841. J Bone Miner Metab 2002;17 Suppl 1:SA 362
Fraher LJ, Avram R, Watson PH, Hendy GN, Henderson JE, Chong KL, et al. Comparison of the biochemical responses to human parathyroid hormone-(1– 31)NH2 and hPTH-(1–34) in healthy humans. J Clin Endocrinol Metab 1999;84 8:2739–43
Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88 2:569–75
Black DM, Rosen CJ. Parsimony with PTH: is a single weekly injection of PTH superior to a larger cumulative dose given daily? J Bone Miner Res 2002;17 suppl 1:SA367
Heaney RP, Recker RR. Combination and sequential therapy for osteoporosis. N Engl J Med 2005;353 6:624–5
Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000;105 11:1595–604
Acknowledgment
Some of the data reported in this review were obtained through support of a grant from the National Institutes of Health (NIDDK 32333).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Girotra, M., Rubin, M.R. & Bilezikian, J.P. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7, 113–121 (2006). https://doi.org/10.1007/s11154-006-9007-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11154-006-9007-z